Amphastar Pharmaceuticals, Inc. (AMPH)

In the past six months, AMPH's stock has trended up by 1.87%, but over the past year, it has trended down by 50.59%. In Q2 2025, Amphastar reported earnings per share (EPS) of $0.85, exceeding analysts' expectations, with BAQSIMI sales surging 21% year-over-year. In Q1 2025, net revenues declined slightly, but BAQSIMI and Primatene Mist sales increased, while Glucagon and Epinephrine sales declined due to increased competition. In Q3 2024, net revenues increased by 6% year-over-year, with Primatene Mist achieving its highest quarterly sales since launch. In October 2025, Zacks Research raised Amphastar Pharmaceuticals from a "hold" to a "strong-buy" rating, and Needham & Company LLC reiterated a "buy" rating with a $36.00 price objective. Bank of America increased its price objective to $32.00 with a "neutral" rating in August 2025, while Piper Sandler lowered its price objective to $25.00 and set a "neutral" rating in August 2025.

Amphastar Pharmaceuticals' product demand does not appear to follow distinct recurring seasonal patterns. Demand can be influenced by specific events and competitive dynamics. For instance, during the first half of 2020, sales of Primatene Mist® and certain hospital products increased due to the COVID-19 pandemic, while products used in elective procedures decreased. In Q1 2025, the company experienced softer demand for critical care products due to increased competition. Competitive pressures and market dynamics play a more significant role in demand fluctuations than inherent seasonal cycles for many of its products.

Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty pharmaceutical company focused on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also produces insulin active pharmaceutical ingredients (APIs). Amphastar operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Amphastar's core business segments include generic pharmaceuticals, proprietary pharmaceuticals, and active pharmaceutical ingredients (APIs). The company's products are primarily used in hospital or urgent care clinical settings and are distributed through group purchasing organizations and drug wholesalers. Major products include BAQSIMI®, a nasal spray for the emergency treatment of severe hypoglycemia acquired from Eli Lilly in April 2023; Primatene Mist®, the only FDA-approved over-the-counter inhaler for temporary relief of mild symptoms of intermittent asthma; Epinephrine Injection, used for the emergency treatment of allergic reactions; Naloxone Injection, a critical medication for opioid overdose reversal; Enoxaparin Sodium Injection, a low molecular weight heparin used to prevent and treat blood clots; Albuterol Sulfate Inhalation Aerosol, an FDA-approved inhalation product launched in August 2024; Glucagon for injection emergency kit; Cosyntropin injection, Phytonadione injection, Lidocaine jelly, and Amphadase hyaluronidase injection.

Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California, in the United States. The company distributes its products through specialty distributors, wholesalers, and retailers in the U.S., France, and China.

In the past year, Amphastar Pharmaceuticals has seen positive developments that contribute to its brand reputation. The company has received FDA approvals for new products, such as Albuterol Sulfate Inhalation Aerosol, and the FDA accepted the application for AMP-004, an insulin biosimilar candidate. The acquisition of Baqsimi has also been a strategic move, with sales surging significantly in Q1 2025. Historically, the company faced criticism in 2015 for doubling the price of naloxone and had an FDA application rejected in 2017, but no specific negative events impacting its brand reputation have been prominently reported in the past year.

Amphastar Pharmaceuticals is owned by 69.45% institutional shareholders and 74.39% Amphastar Pharmaceuticals insiders. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, TD Asset Management Inc, Dimensional Fund Advisors Lp, and State Street Corp. Jack Y. Zhang is the largest individual shareholder, owning 17.51 million shares, representing 37.15% of the company. Mary Z. Luo owns 8.94 million shares, representing 18.97%.